The hospital will enhance its testing and research of blood cancers with the SOPHiA DDM™ Platform
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Instituto Mário Penna is live on the SOPHiA DDM™ Platform. Located in Belo Horizonte, Brazil, the Instituto Mário Penna will use SOPHiA GENETICS’ technology to advance its testing, research, and advance data-driven diagnoses and treatment decisions for blood-related cancers and disorders.
Cancer is the second most common cause of death in Brazil, with 704,000 anticipated new cancer cases expected between 2023 and 2025.1 On a global scale, blood cancers are the fifth most common type of cancer in the world.2 The Instituto Mário Penna specializes in treating patients with cancer and is one of the largest providers of oncology services in Brazil. With 58 beds, the center offers both in-patient and out-patient care, chemotherapy and radiation treatments, clinical laboratory analysis, and surgical care. Instituto Mário Penna has implemented the SOPHiA DDM™ Platform to improve its onsite testing capabilities and to inform more data-driven treatment plans.
“At SOPHiA GENETICS we are committed to accelerating and expanding the use of precision medicine,” said Ricardo Mendonca Filho, PhD., Managing Director, LAPAC, SOPHiA GENETICS. “Instituto Mário Penna is a staple within the cancer-care community in Brazil, and its implementation of the SOPHiA DDM™ Platform shows its commitment to advancing cancer care. We are confident that our AI-based platform will help Instituto Mário Penna generate fast, accurate, and meaningful insights to support researchers and clinicians in making data-driven decisions.”
Advances in diagnostics and treatment of blood cancers depend on timely, cost-effective, and reliable sequencing data. The SOPHiA DDM™ Platform uses NGS to target key variants from FFPE, blood, or bone marrow samples helping lead to fast and accurate detection of variants associated with the disease.
The SOPHiA DDM™ Platform is specifically designed to compute a wide array of genomic variants and continually hones its machine learning algorithms to detect genomic variants associated with rare and challenging cases. Additionally, the SOPHiA DDM™ Platform delivers results that are nearly 100 percent reproducible to provide consistent inter- and intra-run results, ensuring stable and trustworthy sequencing data.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.
Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!
